In a deal aimed at creating scale, France’s BioAlliance Pharma and Denmark’s Topotarget have agreed to combine their orphan oncology assets via a merger agreement. BioAlliance will be the continuing company and its shareholders will own approximately two-thirds of the combined entity. Topotarget’s sole asset is the pan-histone deacetylase (HDAC) inhibitor belinostat, which is awaiting a regulatory decision from the US FDA regarding its approval for the treatment of relapsed or refractory peripheral T-cell lymphoma. Belinostat will complement BioAlliance’s late-stage pipeline, which is led by Phase III Livatag® (doxorubicin Transdrug™) for advanced hepatocellular carcinoma.